Renelle Myers at the 2020 Breath Biopsy Conference

The 2021 Breath Biopsy Conference is scheduled for 12th & 13th October. Click the button to express interest in the next Breath Biopsy Conference:

Express Interest

Talk Abstract:
Lung cancer remains the number one cancer killer globally, largely due to late diagnosis at an incurable stage. Recently, lung cancer screening with Low Dose CT (LDCT) scanning has demonstrated a mortality benefit up to 25%, however many questions remain about patient selection and nodule classification during screening.

Adding breath as a non-invasive biomarker to not only identify high risk patients who would benefit from screening, but also classify the malignancy potential of indeterminate pulmonary nodules detected during screening is the primary goal of our current research.
I will discuss our three current studies aimed at breath biomarker discovery for the early detection of lung cancer.

Speaker Biography:

Dr. Renelle Myers is a Clinical Associate Professor of Medicine at the University of British Columbia, and Clinician Scientist at the BC Cancer Research Institute. She is an interventional Respirologist with a cross appointment in Thoracic Surgery, and Director of Bronchoscopy at Vancouver General Hospital. She is Director of the Leung Breath Lab, the first clinical breath lab in Canada. Her research interests include early diagnosis and screening for lung cancer.

The 2021 Breath Biopsy Conference is scheduled for 12th & 13th October. Click the button to express interest in the next Breath Biopsy Conference:

Express Interest